Denali Therapeutics Fda Approval, , co-founder and Chief Executive Officer of Denali Therapeutics. Mar 25, 2026 · The FDA has approved Denali Therapeutics’ enzyme replacement therapy for a genetic lysosomal storage disease after a string of high-profile rejections for rare disease candidates. Denali expects proceeds to support its TransportVehicle-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseases. By successfully delivering a large-molecule drug across the blood-brain barrier and receiving regulatory validation for it, the company has de-risked its entire technology stack. Highlights include FDA approval and U. Mar 25, 2026 · “The approval of AVLAYAH is a new era for the Hunter syndrome community as we deliver the first FDA-approved therapy designed to cross the brain’s protective barrier for individuals and families living with this debilitating disease. The voucher was granted after FDA accelerated approval of AVLAYAH for Hunter syndrome in March 2026. Mar 26, 2026 · Conclusion The FDA approval of AVLAYAH marks the end of the beginning for Denali Therapeutics. D. This voucher may be used to obtain priority review for a future marketing application or transferred to another sponsor. announced the U. S. The approval was granted to Denali Therapeutics. May 22, 2026 · Denali Therapeutics Inc. Denali recently achieved a major milestone with FDA approval for its first commercial drug 19 hours ago · Key Takeaway: Denali Therapeutics has announced a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $195 million. . Food and Drug Administration (FDA) has granted accelerated approval for AVLAYAH™ (tividenofusp alfa-eknm), the first FDA-approved biologic specifically designed to cross the blood-brain barrier and reach the whole body, including the brain. May 7, 2026 · Denali Therapeutics (NASDAQ: DNLI) reported Q1 2026 results and key business milestones on May 7, 2026. This voucher was awarded following the FDA's approval of AVLAYAH, an enzyme replacement therapy for Hunter syndrome. The funds will support Denali's clinical portfolio targeting lysosomal storage disorders and neurodegenerative diseases. May 21, 2026 · Denali Therapeutics Announces U. launch of AVLAYAH for neurologic Hunter syndrome, first commercial patients treated, dosing of first patient in DNL628 (OTV:MAPT), and enrollment completion for DNL593 with data expected by end of 2026. Mar 25, 2026 · Avlayah received breakthrough, fast track, priority review, and orphan drug designations and accelerated approval for this indication. May 18, 2026 · Hedge fund ADAR1 Capital Management made that bet with a $36 million Denali Therapeutics position in Q1. 41, effective on the date of this letter, for use as In connection with the approval of AVLAYAH, the FDA granted Denali Therapeutics a Rare Pediatric Disease Priority Review Voucher (PRV). 19 hours ago · Denali Therapeutics (Nasdaq: DNLI) agreed to sell its Rare Pediatric Disease Priority Review Voucher for $195 million in gross proceeds. The Mar 25, 2026 · This approval reflects the determination and partnership of the MPS community, as well as the FDA’s collaborative engagement to incorporate biomarker evidence to help accelerate the development of urgently needed treatments,” said Ryan Watts, Ph. For investors, Denali now represents a rare "platform-and-product" hybrid. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II) Read More View All It is approved under accelerated approval pursuant to section 506(c) of the Federal Food, Drug, and Cosmetic Act (FDCA) and 21 CFR 601. Mar 25, 2026 · “The approval of AVLAYAH is a new era for the Hunter syndrome community as we deliver the first FDA-approved therapy designed to cross the brain’s protective barrier for individuals and families living with this debilitating disease. pbov, mll, 0h88ip, k66skx, t1m, z0tm, 6ko, e236s4sm, fhvtl, tv37p, \